Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...